AKS-452
Vaccine candidate against COVID-19
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Protein subunit |
Clinical data | |
Routes of administration | Intramuscular |
Part of a series on the |
COVID-19 pandemic |
---|
![]() |
|
Medical response |
|
![]() |
AKS-452 is a COVID-19 vaccine candidate developed by Akston Biosciences.[1][2]
References
[edit]- ^ "Anti-COVID19 AKS-452 – ACT Study (ACT)". ClinicalTrials.gov. 23 December 2020. NCT04681092. Retrieved 21 March 2021.
- ^ "A study to assess the safety and immunogenicity of Anti-COVID-19 AKS-452 vaccine for SARS-Сov-2 infection in Indian healthy subjects". ctri.nic.in. 11 October 2021. CTRI/2021/10/037269. Retrieved 11 October 2021.
![](http://upload.wikimedia.org/wikipedia/commons/thumb/3/32/Scholia_logo.svg/40px-Scholia_logo.svg.png)
Scholia has a profile for AKS-452 (Q110269780).
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|
![]() | This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
![]() | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |
Retrieved from "https://en.wikipedia.org/w/index.php?title=AKS-452&oldid=1192582884"